Cancer Research AACR Conference on Molecular Diagnostics - 2008  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 44, 525-530, February 1, 1984]
© 1984 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Rofstad, E. K.
Right arrow Articles by Brustad, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rofstad, E. K.
Right arrow Articles by Brustad, T.

Development of Thermotolerance in a Human Melanoma Xenograft1

Einar K. Rofstad2 and Tor Brustad

Norsk Hydro's Institute for Cancer Research and the Norwegian Cancer Society, The Norwegian Radium Hospital, Montebello, Oslo 3, Norway

The kinetics of thermotolerance in a human malignant melanoma grown in athymic mice (BALB/c/nu/nu/BOM) was studied. Local hyperthermia was given by immersing the tumor-bearing leg of the mice into a thermostatically regulated water bath. The tumors were exposed to a priming heat dose of 42.5° for 30 min and, at different fractionation intervals, to graded heat doses at 42.5°. Tumor volumetric tripling time, i.e., the time from the day the first treatment was given to the day the tumor volumes had reached 3 times the initial volumes, was used as measure of response. The thermotolerance ratio, i.e., the ratio of the slopes of the dose-response curves (tumor volumetric tripling time versus heating time) for preheated tumors and single-heated tumors, was used as the measure of thermotolerance. Thermotolerance developed rapidly; the thermotolerance ratio reached a maximum of 4.9 ± 0.3 (S. E.) at 16 hr and then decayed slowly to 1.1 ± 0.1 at 168 hr (7 days). Implications of the present results for treatment of cancer patients with hyperthermia are discussed, and it is concluded that treatment protocols probably should not prescribe more than one hyperthermic treatment per week.

1 Financial support was received from the Norwegian Cancer Society, the Norwegian research Council for Science and the Humanities, and the Nansen Scientific Fund.

2 To whom requests for reprints should be addressed.

Received 6/20/83. Accepted 10/26/83.




This article has been cited by other articles:


Home page
Cancer Res.Home page
G. Kong, R. D. Braun, and M. W. Dewhirst
Characterization of the Effect of Hyperthermia on Nanoparticle Extravasation from Tumor Vasculature
Cancer Res., April 1, 2001; 61(7): 3027 - 3032.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1984 by the American Association for Cancer Research.